^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Waldenstrom Macroglobulinemia
    Drug:Imbruvica (ibrutinib) (BTK inhibitor) +
    Rituxan (rituximab) (CD20 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    10/21/2014
    Excerpt:
    Imbruvica in combination with rituximab is indicated for the treatment of adult patients with WM.
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Waldenstrom’s Macroglobulinaemia/Lymphoplasmacytic Lymphoma: Preferred regimens…Ibrutinib ± rituximab